TerbinafineAllylamine antifungal agent CAS# 91161-71-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 91161-71-6 | SDF | Download SDF |
| PubChem ID | 1549008 | Appearance | Powder |
| Formula | C21H25N | M.Wt | 291.43 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (343.14 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine | ||
| SMILES | CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21 | ||
| Standard InChIKey | DOMXUEMWDBAQBQ-WEVVVXLNSA-N | ||
| Standard InChI | InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Terbinafine is an antifungal medication used to treat fungal infections. It is a potent non-competitive inhibitor of squalene epoxidase from Candida with a Ki of 30 nM.In Vitro:Terbinafine has a primary fungicidal action in vitro against most fungal pathogens, including dermatophytes, and dimorphic and filamentous fungi. Terbinafine specifically inhibits fungal ergosterol biosynthesis at the point of squalene epoxidation. The treated fungal cells rapidly accumulate tlic intermediate squalene and become deficient in the end-product of the pathway, ergosterol[1].In Vivo:Terbinafine is not only active after topical application but is very effective in experimental dermatophytoses following oral administration. In fungi infected guinea-pigs, the skin temperature dropps dramatically after the fourth treatment of terbinafine[2]. References: | |||||
Terbinafine Dilution Calculator
Terbinafine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4314 mL | 17.1568 mL | 34.3136 mL | 68.6271 mL | 85.7839 mL |
| 5 mM | 0.6863 mL | 3.4314 mL | 6.8627 mL | 13.7254 mL | 17.1568 mL |
| 10 mM | 0.3431 mL | 1.7157 mL | 3.4314 mL | 6.8627 mL | 8.5784 mL |
| 50 mM | 0.0686 mL | 0.3431 mL | 0.6863 mL | 1.3725 mL | 1.7157 mL |
| 100 mM | 0.0343 mL | 0.1716 mL | 0.3431 mL | 0.6863 mL | 0.8578 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Terbinafine is an allylamine antifungal agent which has fungicidal activity against a wide variety of dermatophytes, moulds and certain dimorphic fungi, and fungistatic activity against Candida albicans.
- Infractin
Catalog No.:BCN3652
CAS No.:91147-07-8
- SLx-2119
Catalog No.:BCC1954
CAS No.:911417-87-3
- EC 144
Catalog No.:BCC5600
CAS No.:911397-80-3
- MPP dihydrochloride
Catalog No.:BCC7225
CAS No.:911295-24-4
- LY2603618
Catalog No.:BCC3923
CAS No.:911222-45-2
- Cefoselis hydrochloride
Catalog No.:BCC4093
CAS No.:911212-25-4
- Adapalene sodium salt
Catalog No.:BCC4285
CAS No.:911110-93-5
- SB 706504
Catalog No.:BCC5615
CAS No.:911110-38-8
- Isotussilagine
Catalog No.:BCN1985
CAS No.:91108-32-6
- Furowanin A
Catalog No.:BCN4790
CAS No.:911004-72-3
- 3,6,19,23-Tetrahydroxy-12-ursen-28-oic acid
Catalog No.:BCN1310
CAS No.:91095-51-1
- 8-Epidiosbulbin E acetate
Catalog No.:BCN7812
CAS No.:91095-48-6
- 17-AAG Hydrochloride
Catalog No.:BCC1297
CAS No.:911710-03-7
- Chrysothol
Catalog No.:BCN4454
CAS No.:911714-91-5
- Lucyoside B
Catalog No.:BCN7811
CAS No.:91174-19-5
- Ophiopogonin C
Catalog No.:BCN5379
CAS No.:911819-08-4
- H-Met-OtBu.HCl
Catalog No.:BCC2996
CAS No.:91183-71-0
- Noscapine HCl
Catalog No.:BCC3819
CAS No.:912-60-7
- Spantide I
Catalog No.:BCC5808
CAS No.:91224-37-2
- Karavilagenin A
Catalog No.:BCN4455
CAS No.:912329-03-4
- TCB-2
Catalog No.:BCC7421
CAS No.:912342-28-0
- ABT-888 (Veliparib)
Catalog No.:BCC1267
CAS No.:912444-00-9
- Veliparib dihydrochloride
Catalog No.:BCC2076
CAS No.:912445-05-7
- SAG
Catalog No.:BCC6390
CAS No.:912545-86-9
New Polyurethane Nail Lacquers for the Delivery of Terbinafine: Formulation and Antifungal Activity Evaluation.[Pubmed:28263845]
J Pharm Sci. 2017 Jun;106(6):1570-1577.
Onychomycosis is a fungal nail infection. The development of new topical antifungal agents for the treatment of onychomycosis has focused on formulation enhancements that optimize the pharmacological characteristics required for its effective treatment. Polyurethanes (PUs) have never been used in therapeutic nail lacquers. The aim of this work has been the development of new PU-based nail lacquers with antifungal activity containing 1.0% (wt/wt) of Terbinafine hydrochloride. The biocompatibility, wettability, and the prediction of the free volume in the polymeric matrix were assessed using a human keratinocytes cell line, contact angle, and Positron Annihilation Lifetime Spectroscopy determinations, respectively. The morphology of the films obtained was confirmed by scanning electron microscopy, while the nail lacquers' bioadhesion to nails was determined by mechanical tests. Viscosity, in vitro release profiles, and antifungal activity were also assessed. This study demonstrated that PU-Terbinafine-based nail lacquers have good keratinocyte compatibility, good wettability properties, and adequate free volume. They formed a homogenous film after application, with suitable adhesion to the nail plate. Furthermore, the antifungal test results demonstrated that the Terbinafine released from the nail lacquer Formulation A PU 19 showed activity against dermatophytes, namely Trichophyton rubrum.
Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium.[Pubmed:28281037]
Mycopathologia. 2017 Aug;182(7-8):673-679.
Tinea unguium caused by dermatophyte species are usually treated with oral antimycotic, Terbinafine (TBF). To understand the mechanisms of improvement and recalcitrance of tinea unguium by oral TBF treatment, a method of quantifying dermatophyte viability in the nail was developed, and the viability of dermatophytes was analyzed in toenail lesions of 14 patients with KOH-positive tinea unguium treated with oral TBF 125 mg/day for up to 16 weeks. Mycological tests, including KOH examination and fungal culture, and targeted quantitative real-time PCR for internal transcribed spacer (ITS) region, including rRNA, were demonstrated at the initial visit and after 8 and 16 weeks of treatment. Assays in eight patients showed that average ITS DNA amount significantly decreased, to 44% at 8 weeks and 36% at 16 weeks compared with 100% at initial visit. No significant difference was observed between at 8 and 16 weeks, despite the TBF concentration in the nail supposedly more than 10-fold higher than the minimum fungicidal concentration for dermatophytes. This finding suggests the pathogenic dermatophytes in nail lesions could survive in a dormant form, such as arthroconidia, during oral TBF treatment. Both antimycotic activity and nail growth are important factors in treatment of tinea unguium.
New microbial source of the antifungal allylamine "Terbinafine".[Pubmed:28344499]
Saudi Pharm J. 2017 Mar;25(3):440-442.
The isolated active compound "F12" from the culture media of the Streptomyces sp. KH-F12 was identified using different spectroscopic techniques. Both 1D- and 2D-NMR as well as HRESIMS were utilized to characterize the structure of the isolated compound. 'F12" was found to be the known systemic antifungal drug Terbinafine marketed under the name "Lamisil". Full analysis of the COSY, HSQC and HMBC enables the full assignment of proton and carbon atoms. Terbinafine is a synthetic allylamine and is reported here for the first time from natural source.
Impact of a terbinafine-florfenicol-betamethasone acetate otic gel on the quality of life of dogs with acute otitis externa and their owners.[Pubmed:28295766]
Vet Dermatol. 2017 Aug;28(4):386-e90.
BACKGROUND: Treatment of canine otitis externa with owner-administered products can be difficult. OBJECTIVES: To evaluate otic treatment administered by a veterinarian on quality of life (QoL) of dogs with otitis externa and their owners, and on clinical and cytology parameters of otitis; compared to an owner-administered treatment. ANIMALS: Fifty client-owned dogs randomly randomized into two groups and treated for 2 weeks. METHODS: Veterinarians treated Group A dogs with a veterinary licensed otic gel on two occasions at a 1 week interval; owners treated Group B dogs once daily with a veterinary licensed otic drop based product along with twice weekly cleaning. Veterinarians evaluated otitis with the OTI-3 scale and semi-quantitative cytological examination on days 0, 7, 14 and 28. At each visit, owners assessed QoL with a validated questionnaire and pruritus with a Visual Analog Scale. Scores before and after treatment of each group, and differences between groups were analysed statistically. RESULTS: In both groups, all parameters improved significantly. There was a significantly higher improvement of QoL scores, for dogs and owners, in Group A, compared to Group B at all time points (P < 0.05), except for owner QoL on Day 28. There was no difference in improvement of OTI-3 between groups at any time point, whereas Group A cytology scores and pruritus improved significantly more by Day 7 (P = 0.0026 and P = 0.0294, respectively). CONCLUSION: A veterinarian-administered otic gel provided equivalent efficacy and higher QoL to dogs with otitis externa and their owners, compared to an owner-administered topical otic therapy.
